ArticleCardio-oncology (London, England)2026
Survival trends in the management of carcinoid heart disease among patients with neuroendocrine neoplasms.
Article in Cardio-oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundNearly 20% of patients with neuroendocrine tumors (NET) develop carcinoid syndrome (CS), and 20-25% of those with CS develop carcinoid heart disease (CHD). Contemporary risk factors for CHD and prognostic variables in NET management remain limited. This study aimed to characterize the clinical and imaging factors associated with the development, and prognostic impact of carcinoid heart disease in patients with neuroendocrine neoplasms.
methodsA single-institution, retrospective analysis of well-differentiated NET patients from January 2010 to December 2024 was conducted. Cox proportional hazards regression assessed associations between baseline covariates and CHD development (primary endpoint) and overall survival (OS; secondary endpoint). CHD was defined as moderate or severe tricuspid regurgitation on echocardiogram with echocardiographic features consistent with carcinoid valvulopathy. Survival curves were estimated using Kaplan-Meier methods. A p-value < 0.05 was considered significant.
resultsWe identified 270 patients with NET. Median age was 64.5 years; 52% were male; 5.6% developed CHD. CS was present in 10% (n = 27), and 41% of those with CS developed CHD. Fifteen patients (5.6%) developed carcinoid heart disease. Common primary sites were lung (26%), pancreas (17.4%), and small intestine (16.2%). CHD was associated with more hospitalizations and greater use of systemic or multimodal therapies. For OS, median OS for CHD patients was 90.8 months, while median OS was not reached for the full NET cohort. CHD independently predicted worse OS (HR 7.09; 95% CI: 1.84-27.40; p = 0.004). Systemic therapy use (HR 8.97; p = 0.0101) and high-grade tumors (HR 6.92; p < 0.001) were also associated with worse OS.
conclusionIn NET patients, CHD and high-grade tumors were associated with worse OS. Systemic therapy use was associated with worse overall survival, likely reflecting more advanced disease rather than a causal treatment effect. Although CHD incidence is low, early detection and close monitoring remain essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.